- Recruiting
NCT04155749: Phase 1 : CART-ddBCMA - Master Protocol for Cell Therapies in Multiple Myeloma
Updated: Aug 27, 2022
NCT04155749: Phase 1: Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma
Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma
Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
ARM 1 is a non-randomized, open label, multi-site Phase 1 study. CART-ddBCMA is a BCMA directed CAR with a non-scFv binding domain that has been deimmunized.
ARM 2 is a non-randomized, open label, multi-site Phase 1 study. Using the bivalent BCMA-Specific Adapter (SPRX001) and Universal CAR-Modified T cell (ARC-T Cells)
Sponsor
Multiple Locations
ClinicalTrials.gov Identifier: NCT04155749
Official Title: Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up
First Posted : November 7, 2019
Click here to see details on ClinicalTrials.gov
Drug: CART-ddBCMA
Drug: ARC-T Plus Anti-BCMA SparX
Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA (Code C167337)
Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA
Anti-TAG ARC-T Cells Directed by BCMA Bi-valent/TAG SparX Protein
ARC-T Plus Anti-BCMA SparX
Immunotherapeutic Combination Agent SparX Protein Plus CART-ddBCMA
TAG-containing SparX /Bivalent BCMA-targeted ARC-T Cells
Meeting: 2022 ASCO Annual Meeting - Session Type: Oral Abstract Session - Session Title: Hematologic Malignancies—Plasma Cell Dyscrasia - Track: Hematologic Malignancies - Sub Track: Hematologic Malignancies - Clinical Trial Registration Number: NCT04155749
Abstract#: 8003 - Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma.
ABSTRACTS & PRESENTATIONS
2022 ASCO ANNUAL MEETING - June 3-7, 2022 - McCormick Place, Chicago, IL - Hybrid Meeting
2022 ASCO Annual Meeting - Oral Abstract Session
Arcellx To Present New Clinical Data From Its CART-DdBCMA Phase 1 Trial In Patients With Relapsed Or Refractory Multiple Myeloma In An Oral Abstract Session At The 2022 American Society Of Clinical Oncology (ASCO) Annual Meeting
NEWS PROVIDED BY Arcellx, Inc Apr 27, 2022, 10:00 ET
FOSTER CITY, Calif., April 27, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that new clinical data from its Phase 1 Study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma will be presented in an oral abstract session at the 2022 ASCO Annual Meeting taking place June 3-7, 2022, in Chicago, Illinois.
Research Article| April 25, 2022
Phase 1 Study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
CART-ddBCMA are safe for use in patients with relapsed or refractory multiple myeloma
CART-ddBCMA produce deep and durable responses in patients with poor prognostic factors
3832 Phase 1 Study of CART-Ddbcma, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma
Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Clinical: Poster III
Hematology Disease Topics & Pathways:
Clinical Trials, Biological, Cytokine Release Syndrome, Adults, Neurotoxicity, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Elderly, Clinically Relevant, Diseases, Therapies, Immunotherapy, Lymphoid Malignancies, Adverse Events, Study Population
Monday, December 13, 2021, 6:00 PM-8:00 PM
Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 63rd ASH Annual Meeting and Exposition
December 13, 2021 09:00 ET | Source: Arcellx, Inc.
FOSTER CITY, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Arcellx, Inc., a privately held clinical-stage biopharmaceutical company, today announced new positive clinical data from the ongoing Phase 1 expansion study of its novel, autologous, CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma. The clinical results are being presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
Meeting Abstract | 2021 ASCO Annual Meeting I
Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma.
3199 Phase 1 Study of CART-Ddbcma, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma
Program: Oral and Poster Abstracts
Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster III
Hematology Disease Topics & Pathways:
Biological, Adult, bioengineering, Therapies, CAR-Ts, Elderly, gene therapy, Technology and Procedures, immunotherapy, gene editing, Study Population, Clinically relevant
Monday, December 7, 2020, 7:00 AM-3:30 PM
OAB-003 - Phase 1 study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain for the treatment of subjects with relapsed and refractory multiple myeloma
#IMS2022 - 19th International Myeloma Society Annual Meeting; August 25-27, 2022 - LA, California
Locations
United States, Illinois
United States, Massachusetts
United States, Wisconsin